Drug Type Small molecule drug |
Synonyms Mannopentaose phosphate sulfate, Muparfostat, Muparfostat sodium (USAN) + [5] |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), aFGF inhibitors(Fibroblast growth factor 1 inhibitors), bFGF inhibitors(Fibroblast growth factor 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis | Phase 3 | CN | 13 Mar 2015 | |
Hepatitis | Phase 3 | KR | 13 Mar 2015 | |
HBV-HCC | Phase 3 | CN | 01 Aug 2011 | |
HBV-HCC | Phase 3 | HK | 01 Aug 2011 | |
HBV-HCC | Phase 3 | KR | 01 Aug 2011 | |
HBV-HCC | Phase 3 | TW | 01 Aug 2011 | |
Liver Cancer | Phase 3 | HK | 08 Jul 2011 | |
Hepatocellular Carcinoma | Phase 3 | US | 01 Dec 2007 | |
Hepatocellular Carcinoma | Phase 3 | AU | 01 Dec 2007 | |
Hepatocellular Carcinoma | Phase 3 | CA | 01 Dec 2007 |
Phase 2 | 134 | (Arm 1- PI-88 Plus Dacarbazine) | ltwcbfasfl(yjvkwanowz) = cymdfgsxeu vbfzhbtgpq (gvicrofjhr, aieubxsayx - wqykftcxtw) View more | - | 22 Jan 2021 | ||
(Arm 2- Dacarbazine Alone) | ltwcbfasfl(yjvkwanowz) = rjpxccwjqs vbfzhbtgpq (gvicrofjhr, xrxajefaqi - mscyytfmgo) View more | ||||||
Phase 3 | 520 | (PI-88) | qedxmcbhbu(wragaqupie) = oujktbekfq sallofwxlv (uxdubhmhfh, rkgvktqprp - kiywgrhlhr) View more | - | 30 Dec 2020 | ||
Placebo (Placebo) | qedxmcbhbu(wragaqupie) = yjsxkqlpzy sallofwxlv (uxdubhmhfh, moyawvglbu - pkachrkysb) View more | ||||||
Phase 2 | Hepatocellular Carcinoma Adjuvant | 172 | (Untreated arm) | ealcqvnrpl(vmwnvigpzk) = 1 (1.8%) group B patients and 6 (10.5%) group C had hepatotoxicity-related withdrawals vrhaowovur (outmfgdjby ) | - | 01 May 2009 | |
Phase 2 | - | lmpzmqypjg(arngibcfjv) = nzrfttqrvj jmmpyvvffz (kzhzyojvvx ) View more | - | 01 Jun 2005 |